Regarding adverse events, 13 studies provided data on AKI [28–32, 34, 35, 41, 42, 44, 45, 47, 48], 5 studies reported on CDI [35, 41, 42, 44, 47], 5 studies examined elevated CPK levels [28, 40–42, 48], and 3 studies addressed thrombocytopenia [30, 34, 44]. This evidence concerns the gene PIK3C2A and Thrombocytopenia.